Douglas Muchmore, M.D.

Chief Technology Officer

Dr. Muchmore joined Diasome in 2016 and has led the execution of multiple HDV Insulin human clinical trials, including the Company’s ISLE-1 Phase 2b study of HDV Insulin in patients with Type 1 diabetes.  He has been a clinical consultant working almost exclusively in diabetes-related endeavors for the past four years.

Previously, Dr. Muchmore worked as a consulting endocrinologist at Scripps Clinic and Research Foundation. He received his medical degree from University of California San Diego School of Medicine. He has held and continues to hold numerous consulting and medical advisory roles for large pharmaceutical companies, including Eli Lilly, Halozyme Therapeutics and Kinexum Services.


Scientific advisory board

Board of directors

10000 Cedar Avenue
Suite 6
Cleveland, OH 44106

Media Contact

Kent Manson